Xeris Pharmaceuticals, Inc. is a fast-growing biopharmaceutical company dedicated to improving patients’ lives through the development and commercialization of innovative therapies. Xeris markets three products treating severe hypoglycemia, endogenous Cushing’s syndrome, and primary periodic paralysis, while advancing a pipeline of internal and partnered programs enabled by its proprietary formulation science.